Asthma does not influence the severity of COVID-19: a meta-analysis

J Asthma. 2022 Jun;59(6):1188-1194. doi: 10.1080/02770903.2021.1917603. Epub 2021 Apr 23.

Abstract

Objective: Previous studies have reported a correlation between coronavirus disease-2019 (COVID-19) and asthma. However, data on whether asthma constitutes a risk factor for COVID-19 and the prevalence of asthma in COVID-19 cases still remain scant. Here, we interrogated and analyzed the association between COVID-19 and asthma.

Methods: In this study, we systematically searched PubMed, Embase, and Web of Science databases for studies published between January 1 and August 28, 2020. We included studies that reported the epidemiological and clinical features of COVID-19 and its prevalence in asthma patients. We excluded reviews, animal trials, single case reports, small case series and studies evaluating other coronavirus-related illnesses. Raw data from the studies were pooled into a meta-analysis.

Results: We analyzed findings from 18 studies, including asthma patients with COVID-19. The pooled prevalence of asthma in COVID-19 cases was 0.08 (95% CI, 0.06-0.11), with an overall I2 of 99.07%, p < 0.005. The data indicated that asthma did not increase the risk of developing severe COVID-19 (odds ratio [OR] 1.04 (95% CI, 0.75-1.46) p = 0.28; I2=20%). In addition, there was no significant difference in the incidence of asthma with age in COVID-19 infections [OR] 0.77(95% CI, 0.59-1.00) p = 0.24; I2=29%).

Conclusion: Taken together, our data suggested that asthma is not a significant risk factor for the development of severe COVID-19.

Keywords: Asthma; COVID-19; atopic disease; epidemic; meta-analysis.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Asthma* / epidemiology
  • COVID-19* / epidemiology
  • Humans
  • Prevalence
  • Risk Factors
  • SARS-CoV-2